
Changmugu Medical
Changmugu Medicalis an artificial intelligence (AI)-powered healthcare start-up.
Date | Investors | Amount | Round |
---|---|---|---|
N/A | €0.0 | round | |
investor investor | €0.0 | round | |
$84.3m | Series B | ||
Total Funding | 000k |
Related Content
Beijing Changmugu Medical Technology Co., Ltd. operates at the intersection of artificial intelligence and orthopedic surgery, providing integrated intelligent solutions for hospitals. Founded in 2018, the company has established its headquarters in Beijing, China. The founding team, which includes CEO Zhang Yiling, Chairman Liu Xingyu, and co-founder An Yicheng, possesses a blend of medical and engineering expertise from institutions like Harvard and Tsinghua University. Zhang Yiling, formerly a researcher at Harvard Medical School with over a decade of experience in orthopedic clinical practice and research, identified a critical need for better pre-operative planning tools in China to improve surgical precision.
The company targets orthopedic departments in hospitals, offering a suite of products that cover the entire surgical workflow. This includes AI-assisted diagnosis, individualized surgical planning, 3D-printed patient-specific instrumentation (PSI) surgical guides, surgical robots, and post-operative evaluation services. Its core offering, the AIJOINT® system, is an AI-powered platform for joint replacement surgery that can convert 2D CT scans into 3D models, allowing surgeons to simulate and rehearse procedures beforehand. This process aims to enhance the accuracy of implant selection and placement, potentially reducing complications like leg length discrepancy and improving patient outcomes.
Revenue is generated through the sale and service of these high-tech medical solutions. Changmugu has developed specific products like AIHIP and AIKNEE for hip and knee replacements, respectively, and the ROPA series of surgical robots. The company has secured significant funding to fuel its growth, including a Series B round of 540 million yuan ($84.3 million) in 2021. This capital is being used for new product R&D, clinical trials, production expansion, and global marketing. A key strategic partnership with Johnson & Johnson Medical China, initiated in 2019, focuses on the joint development and commercialization of digital orthopedic solutions, highlighting a collaborative business approach to penetrate the market.
Keywords: orthopedic AI, surgical robotics, medical technology, digital surgery, joint replacement, 3D surgical planning, surgical navigation, medical imaging, HealthTech, AI-assisted diagnosis, patient-specific instruments, surgical simulation, knee replacement, hip replacement, ROPA robot, AIJOINT, medical devices, clinical solutions, precision medicine, MedTech